文献速递妇科肿瘤

2022年欧洲癌症死亡率预测:聚焦卵巢癌

European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
PubMed 文献 · Ann Oncol · 2022-01-26

该研究基于世界卫生组织与欧盟统计局1970年以来的死亡证明和人口数据,预测欧盟、英国、法国、德国、意大利、波兰和西班牙2022年癌症死亡率。欧盟2022年预计癌症死亡1269200例,年龄标化率男性降至126.9/10万(降6%),女性降至80.2/10万(降4%);卵巢癌死亡率在所有考虑国家过去十年均下降,欧盟全年龄段预测为4.3/10万(降13%)。

要点

  • 欧盟2022年预计癌症死亡1269200例,年龄标化率男性126.9/10万(较2017年降6%),女性80.2/10万(降4%)。
  • 胰腺癌在欧盟成为第三位癌症死因(87300例),超过乳腺癌(86300例);男性稳定于8.1/10万,女性上升3%至5.9/10万。
  • 卵巢癌死亡率在全部考虑国家过去十年下降,欧盟全年龄段4.3/10万(降13%),20-49岁1.2/10万(降26%)。

核心结论

  • 预测2022年欧洲癌症死亡率进一步下降;女性肺癌死亡率上升放缓反映女性吸烟趋于平稳;卵巢癌 favorable 趋势可能持续,主要归因于口服避孕药普及及诊断和治疗改善的部分影响。

研究设计与样本

  • 使用世界卫生组织与欧盟统计局1970年以来的癌症死亡证明和人口数据,对欧盟、英国、法国、德国、意大利、波兰和西班牙1989至2022年总癌症及10个主要部位的死亡率进行预测并估算避免死亡数。

主要发现

  • 欧盟2022年预测癌症死亡1269200例;年龄标化率(世界)男性下降6%至126.9/10万,女性下降4%至80.2/10万(自2017年)。
  • 男性肺癌预计下降10%至30.9/10万;女性肺癌死亡率上升放缓(+2%至13.8/10万)。
  • 仅2022年估计避免死亡369000例(23%),自1988年峰值率以来累计避免死亡5394000例(12%)。
  • 胃癌、结直肠癌、乳腺癌和前列腺癌过去5年下降5%至16%;胰腺癌男性稳定于8.1/10万,女性上升3%至5.9/10万,成为欧盟第三位癌症死因(87300例),超过乳腺癌(86300例)。
  • 子宫癌下降放缓(-4%)至4.7/10万;膀胱癌男性下降9%,女性稳定;白血病下降超过10%。

关键数值与推荐

  • 卵巢癌死亡率过去十年在所有考虑国家下降;欧盟预测率全年龄段4.3/10万(-13%),20-49岁1.2/10万(-26%),50-69岁15.3/10万(-11%),70-79岁32.3/10万(-11%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer mortality rates, though not absolute numbers of deaths, have been decreasing over the last three decades in Europe. MATERIALS AND METHODS: We estimated projections and the number of avoided deaths for total cancer mortality and 10 major cancer sites, between 1989 and 2022, for the European Union (EU), the UK, France, Germany, Italy, Poland and Spain using cancer death certification and population data since 1970 from the World Health Organization and Eurostat. RESULTS: In the EU, we predict 1 269 200 cancer deaths in 2022; corresponding age-standardized rates (world) fall 6% to 126.9 deaths/100 000 in men and 4% to 80.2/100 000 women since 2017. Male lung cancer is expected to fall 10% reaching 30.9/100 000. The rise in female lung cancer mortality slowed (+2% to 13.8/100 000). We estimated 369 000 (23%) avoided deaths in 2022 alone and a total of 5 394 000 (12%) deaths since the peak rate in 1988. Stomach, colorectal, breast and prostate cancers showed substantial declines, between 5% and 16% over the past 5 years. Pancreatic cancer remained stable in men (8.1/100 000) and rose 3% in women (5.9/100 000), becoming the third cause of cancer mortality in the EU (87 300 deaths), overtaking breast cancer (86 300 deaths). The fall in uterine cancers slowed down (-4%) to 4.7/100 000. Bladder cancer fell 9% in men, but was stable in women. Leukaemias fell more than 10%. Ovarian cancer mortality declined over the past decade in all considered countries. EU predicted rates were 4.3/100 000 (-13%) all ages, 1.2/100 000 (-26%) at 20-49, 15.3/100 000 (-11%) at 50-69 and 32.3/100 000 (-11%) at 70-79 years. CONCLUSIONS: We predicted additional declines in cancer mortality rates for 2022. The slowdown in female lung cancer mortality reflects some levelling of smoking in women. Favourable ovarian cancer trends are likely to continue and are largely attributable to the spreading oral contraceptive use and some impact of improved diagnosis and management.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dalmartello M, La Vecchia C, Bertuccio P, et al. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022. PMID: 35090748. doi:10.1016/j.annonc.2021.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。